{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-004525","form_type":"8-K","ticker":"BCTX","cik":"0001610820","company_name":"BriaCell Therapeutics Corp.","filed_at":"2024-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.804688+00:00","generated_at":"2026-06-06T13:34:41.146527+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"BriaCell shareholders ratify MNP as auditor and re-elect all seven director nominees at AGM","bullets":["Ratified MNP LLP as independent auditor with 5,346,102 For, 0 Against, 28,968 Withheld.","Re-elected all seven directors: Gross, Lustig, Bondarenko, Williams, Taub, Embro-Pantalony, Schmieg.","Voter turnout: 5,375,071 common shares represented (33.6% of 15,981,726 outstanding shares) – quorum met."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-004525","json":"https://secwatch.observer/filing/0001493152-24-004525.json","markdown":"https://secwatch.observer/filing/0001493152-24-004525.md","text":"https://secwatch.observer/filing/0001493152-24-004525.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610820/000149315224004525/0001493152-24-004525-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610820/000149315224004525/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T13:34:41.146527+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a636e67f307b1e08d14fc23d15097adea97106a0","claim":"BriaCell Therapeutics Corp. shareholders approved Ratification of appointment of MNP LLP as auditors at the 2024-01-30 meeting.","evidence_excerpt":"Proposal 1. At the Meeting, the shareholders ratified the appointment of MNP LLP as auditors for the Company and the authorization of the Board of Directors of the Company (the \"Board\") to fix the auditors' remuneration and terms of engagement.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1610820/000149315224004525/0001493152-24-004525-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-01-30"}],"fact_type":"shareholder_vote"},{"claim_id":"cbcd02f535a34d952f2c77d4c09f331b886c3c02","claim":"BriaCell Therapeutics Corp. shareholders approved Election of seven director nominees at the 2024-01-30 meeting.","evidence_excerpt":"Proposal 2. At the Meeting, the terms of seven (7) members of the Board expired. Each of the seven (7) nominees for director (the \"Nominees\") were elected to serve until the next annual meeting of shareholders, or until his/her successor is duly elected or appointed, unless he/she resigns, is removed, or becomes disqualified in accordance with the Articles of Incorporation of the Company or the British Columbia Corporations Act.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1610820/000149315224004525/0001493152-24-004525-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2024-01-30"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}